Mr. Matthew Wong, Chief Executive Officer of Pyrinas, commented, “These cities have been selected in view of several crucial factors that we believe are best positioned to take advantage of the robust growth in the life science industry. The fund will focus on acquisition and development of real estate suitable for the healthcare and life science sector, particularly in operating laboratories with a co-working space model. We are seeing increasingly robust demand for space by life science companies and start-ups, who are encouraged by the rapidly growing venture capital investment market in North America.”
The fund is targeting a launch size of up to US$120 million with a targeted return of 15-19% per annum (Net IRR) over a period of four years with one-year extension. Pyrinas is currently in discussions with a number of institutional investors and collaborative partners.
Together with its affiliated company Aptorum Group Limited (Nasdaq: APM) and Aeneas Capital, the fund also aims to nurture medical research, the development of intellectual property, and collaboration between scientists, researchers, investors, and industry participants; while providing real estate solutions that foster an ecosystem for collegial interactions among industry, investors, government and academia.
The fund is targeted for institutional and professional investors only and subject to restrictions in certain jurisdictions.
About the Group
Pyrinas Real Estate Management Limited (”Pyrinas”), the real estate arm of Aeneas Group and an affiliate of Aptorum Group, was established in 2018. Pyrinas currently is managing two laboratory facilities and one clinic facility in Hong Kong. For more information about Pyrinas, please visit www.pyrinasgroup.com.
Aeneas Group Limited, the parent company of Aeneas Capital Limited (“ACL”), is a multi-disciplinary financial institution with cross border capabilities and technology services. For more information about Aeneas Group Limited, please visit www.aeneasgroup.com.
Aptorum Group Limited (Nasdaq : APM) is a biopharmaceutical company currently developing a portfolio of therapeutic candidates and medical devices, and is dedicated to developing and commercializing its portfolio of technologies to tackle unmet medical needs observed globally. For more information about Aptorum Group Limited, please visit www.aptorumgroup.com.
Disclaimer. The information contained in this press release should not be construed as an offer of, or a solicitation for an investment in, securities or any other financial instrument in any jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005721/en/
출처:Pyrinas Real Estate Management Limited
언론연락처: Pyrinas Real Estate Management Limited Pyrinas +852 3469 7903
이 뉴스는 기업·기관이 발표한 보도자료 전문입니다.
보도자료 출처 : Pyrinas Real Estate Management Limited
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
<저작권자 © BS뉴스-비에스뉴스, 무단 전재 및 재배포 금지>